MediciNova, Inc. announced that it has received an issue notification from the U.S. Patent and Trademark Office for a new patent which covers extended-release oral formulations of MN-166 (ibudilast). This new patent is expected to commence no earlier than September 2040. The allowed claims cover a formulation in the form of a tablet or capsule and cover a range of doses of MN-166 (ibUDilast).
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.36 USD | +2.26% | +1.49% | -9.33% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-9.33% | 66.7M | |
+11.91% | 118B | |
+11.60% | 106B | |
-4.68% | 24.28B | |
-0.82% | 21.96B | |
-10.12% | 18.16B | |
-42.12% | 16.37B | |
-17.47% | 15.56B | |
+2.77% | 13.63B | |
+34.58% | 12.27B |
- Stock Market
- Equities
- MNOV Stock
- News MediciNova, Inc.
- MediciNova, Inc. Receives Issue Notification for New Patent Covering Extended-Release Formulations of MN-166